{
  "resourceType" : "ValueSet",
  "id" : "2.16.840.1.113762.1.4.1034.582",
  "meta" : {
    "versionId" : "17",
    "lastUpdated" : "2021-03-09T01:00:17.000-05:00",
    "profile" : [
      "http://hl7.org/fhir/StructureDefinition/shareablevalueset",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
    ]
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author",
      "valueString" : "American Academy of Neurology Author"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
      "valueDate" : "2022-12-15"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
      "valueDate" : "2021-03-09"
    }
  ],
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.582",
  "identifier" : [
    {
      "system" : "urn:ietf:rfc:3986",
      "value" : "urn:oid:2.16.840.1.113762.1.4.1034.582"
    }
  ],
  "version" : "20210309",
  "name" : "DiabetesScreeningWithFastingComponentLOINC",
  "title" : "Diabetes Screening with Fasting Component (LOINC)",
  "status" : "active",
  "experimental" : false,
  "date" : "2021-03-09T01:00:17-05:00",
  "publisher" : "American Academy of Neurology Steward",
  "jurisdiction" : [
    {
      "extension" : [
        {
          "url" : "http://hl7.org/fhir/StructureDefinition/data-absent-reason",
          "valueString" : "UNKNOWN"
        }
      ]
    }
  ],
  "purpose" : "(Clinical Focus: This value set contains LOINC concepts for diabetes screening with a fasting component excluding gestational diabetes.),(Data Element Scope: The intent of this data element is to identify people who have participated in diabetes screening with a fasting component.),(Inclusion Criteria: The intent of this data element is to identify people who have participated in diabetes screening with a fasting component.),(Exclusion Criteria: Excludes screening or assessment without a fasting component and for gestational diabetes and blood glucose screening methods using bodily substances other than blood or urine.)",
  "compose" : {
    "include" : [
      {
        "system" : "http://loinc.org",
        "concept" : [
          {
            "code" : "21004-7",
            "display" : "Glucose tolerance [Interpretation] in Serum or Plasma"
          },
          {
            "code" : "49688-5",
            "display" : "Glucose tolerance [Interpretation] in Serum or Plasma Narrative--post 75 g glucose PO"
          },
          {
            "code" : "50586-7",
            "display" : "Glucose tolerance 3 hours panel - Serum or Plasma"
          },
          {
            "code" : "50587-5",
            "display" : "Glucose tolerance 4 hours panel - Serum or Plasma"
          },
          {
            "code" : "50588-3",
            "display" : "Glucose tolerance 5 hours panel - Serum or Plasma"
          },
          {
            "code" : "50589-1",
            "display" : "Glucose tolerance 6 hours panel - Serum or Plasma"
          },
          {
            "code" : "55399-0",
            "display" : "Diabetes tracking panel"
          },
          {
            "code" : "72171-2",
            "display" : "Glucose tolerance 2 hours panel - Serum or Plasma"
          },
          {
            "code" : "93794-6",
            "display" : "Glucose tolerance and insulin sensitivity 2 hour panel - Serum or Plasma"
          }
        ]
      }
    ]
  },
  "expansion" : {
    "identifier" : "urn:uuid:e6cbf7be-0e93-4735-963b-71f808f01bdd",
    "timestamp" : "2023-06-29T17:00:16-04:00",
    "total" : 9,
    "offset" : 0,
    "parameter" : [
      {
        "name" : "count",
        "valueInteger" : 1000
      },
      {
        "name" : "offset",
        "valueInteger" : 0
      }
    ],
    "contains" : [
      {
        "system" : "http://loinc.org",
        "version" : "2.74",
        "code" : "21004-7",
        "display" : "Glucose tolerance [Interpretation] in Serum or Plasma"
      },
      {
        "system" : "http://loinc.org",
        "version" : "2.74",
        "code" : "49688-5",
        "display" : "Glucose tolerance [Interpretation] in Serum or Plasma Narrative--post 75 g glucose PO"
      },
      {
        "system" : "http://loinc.org",
        "version" : "2.74",
        "code" : "50586-7",
        "display" : "Glucose tolerance 3 hours panel - Serum or Plasma"
      },
      {
        "system" : "http://loinc.org",
        "version" : "2.74",
        "code" : "50587-5",
        "display" : "Glucose tolerance 4 hours panel - Serum or Plasma"
      },
      {
        "system" : "http://loinc.org",
        "version" : "2.74",
        "code" : "50588-3",
        "display" : "Glucose tolerance 5 hours panel - Serum or Plasma"
      },
      {
        "system" : "http://loinc.org",
        "version" : "2.74",
        "code" : "50589-1",
        "display" : "Glucose tolerance 6 hours panel - Serum or Plasma"
      },
      {
        "system" : "http://loinc.org",
        "version" : "2.74",
        "code" : "55399-0",
        "display" : "Diabetes tracking panel"
      },
      {
        "system" : "http://loinc.org",
        "version" : "2.74",
        "code" : "72171-2",
        "display" : "Glucose tolerance 2 hours panel - Serum or Plasma"
      },
      {
        "system" : "http://loinc.org",
        "version" : "2.74",
        "code" : "93794-6",
        "display" : "Glucose tolerance and insulin sensitivity 2 hour panel - Serum or Plasma"
      }
    ]
  }
}
